No Data
No Data
Ardelyx Down as H.C. Wainwright Downgrades Rating on Anticipated Xphozah Sales Drop
Improved Revenues Required Before Ardelyx, Inc. (NASDAQ:ARDX) Shares Find Their Feet
H.C. Wainwright Downgrades Ardelyx(ARDX.US) to Hold Rating, Cuts Target Price to $5.5
Express News | Ardelyx Inc : H.c. Wainwright Cuts to Neutral,
Express News | Ardelyx Responds to District Court Decision Granting Motion to Dismiss
Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference
Tom’s Jerry : Why do you have so much faith in this stock? Is there any advantage that we don't know about?
Richard Fain Fan OP Tom’s Jerry : Yeah. An over reaction by pussy retail investors, we’ll take it to the Supreme Court. fundamentals still there. Top drug not even priced in. Trading at only 2x multiples. Big money gobbling this up.